Xenon Pharmaceuticals (XENE)
(Delayed Data from NSDQ)
$40.50 USD
+0.40 (1.00%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $40.53 +0.03 (0.07%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Earnings News For XENE
-
Xenon (XENE) Q4 Earnings Top Estimates, Pipeline in Focus
-
Xenon Pharmaceuticals: Q4 Earnings Snapshot
-
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
-
Xenon Pharmaceuticals: Q3 Earnings Snapshot
-
Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
-
Xenon Pharmaceuticals (XENE) Reports Q2 Loss, Misses Revenue Estimates
-
Xenon Pharmaceuticals: Q2 Earnings Snapshot
-
Xenon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
-
Xenon Pharmaceuticals (XENE) Reports Q1 Loss, Lags Revenue Estimates
-
Xenon Pharmaceuticals: Q1 Earnings Snapshot
-
Xenon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
-
Xenon Pharmaceuticals (XENE) Expected to Beat Earnings Estimates: Should You Buy?
-
Xenon Pharmaceuticals (XENE) Reports Q4 Loss, Lags Revenue Estimates
-
Xenon Pharmaceuticals: Q4 Earnings Snapshot
-
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
-
Xenon Pharmaceuticals (XENE) Reports Q3 Loss, Misses Revenue Estimates
-
Xenon Pharmaceuticals: Q3 Earnings Snapshot
-
Xenon Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-
Xenon Pharmaceuticals (XENE) Reports Q2 Loss, Misses Revenue Estimates
-
Xenon Pharmaceuticals: Q2 Earnings Snapshot
-
Xenon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
-
Xenon Pharmaceuticals (XENE) Reports Q1 Loss, Misses Revenue Estimates
-
Xenon Pharmaceuticals (XENE) Reports Q4 Loss, Lags Revenue Estimates
-
Xenon Pharmaceuticals (XENE) Reports Q3 Loss, Tops Revenue Estimates
-
Earnings Preview: Xenon Pharmaceuticals (XENE) Q3 Earnings Expected to Decline